Efficacy and safety of combined targeted therapy and immunotherapy versus targeted monotherapy in older patients with uHCC

Efficacy and safety of combined targeted therapy and immunotherapy versus targeted monotherapy in older patients with uHCC

BackgroundThe prevalence of hepatocellular carcinoma (HCC) among older patients is rising due to the aging population. This study aimed to compare the efficacy and safety of targeted therapy alone versus its combination with immunotherapy in older patients (≥ 65 years old) with unresectable HCC (uHC...

Full description

Saved in:
Bibliographic Details
Main Authors: Yu Li, Jian-Hong Zhong, Xiao-Dong Zhu, Chuang-Ye Han, Jia-Bei Wang, Hong-Zhi Liu, Kuan Hu, Yang-Xun Pan, Hui-Chuan Sun, Tao Peng, Lian-Xin Liu, Yong-Yi Zeng, Le-Du Zhou, Li Xu, Nan-Ya Wang
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-04-01
Series:Frontiers in Oncology
Subjects:
hepatocellular carcinoma
older patients
targeted monotherapy
PD-1/PD-L1 combination therapy
clinical outcome
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2025.1515640/full
Tags: Add Tag
No Tags, Be the first to tag this record!
Be the first to leave a comment!
You must be logged in first

Similar Items